EHA 2025 | An overview of advances in myeloma treatment and updated trial findings from EHA 2025

We are here at EHA 2025 in Milan where the therapeutic and diagnostic revolution in multiple myeloma is going to continue starting from frontline setting where we can see that isatuximab is more and more becoming a potential new backbone thanks to data in transplant eligible with GMMG and imroz for transplant ineligible population. Let’s not forget also the update of Perseus trial and Celaenus trial respectively transplant eligible and not eligible in terms of deepness of response and MRD negativity. The smoldering myeloma is going to be more and more treated particularly at high risk. We have seen here an important meta-analysis confirming our idea that it’s really important to treat as soon as possible particularly the high-risk patient. Let’s go on relapsed refractory status. I think that an outstanding result is the ICARIA, a clinical trial in which we can see finally the subcutaneous administration of isatuximab versus intravenous with a non-inferiority in terms of effectiveness but particularly also with an important confirmation of quality of life, of absence of infusion reaction and also satisfaction of the personnel. The nurses based questionnaires show incredible results and I think that this is a basis not only for this combination but also for the next future of multiple myeloma because the subcutaneous administration performed via on-body delivery system that is a small button put on the abdomen of the patient in which the drug is injected so without any risk for administration can be a basis also for being integrated in other triplet and quadruplet isatuximab-based so they can make a wider use of this drug. Let’s not forget the data with CAR-T that in my opinion are the most outstanding data from this conference, particularly the ones from CARTITUDE-1 that has shown 33% of five years of progression-free survival. Incredible data if we consider the difficult to treat population really super heavily pretreated the patient. But also CARTITUDE-4 in terms of MRD negativity and in terms of superiority also in difficult to treat patients such as extramedullary disease is something that is going to change our next future daily approach. Bispecific antibodies has shown improving in terms of updates from clinical trials but in my opinion, the most outstanding data is the ones coming from the real world that confirms that also in community centers these are feasible, effective and well tolerable. I think that we have to consider also that the combinations are arriving and in my opinion, linvoseltamab with carfilzomib is a potential game changer in terms of effectiveness, fast response and tolerability. Trispecific antibodies are arriving. This is another hope for us and for our patients. I think that the data are brilliant, but we need to increase the number of the patients. Anito-cel is a potential other CAR-T that is going to be integrated in our general therapeutic panorama of multiple myeloma. For heavily-pretreated patients, we are going to explore new combinations, challenges, and so on. We need to cover the lenalidomide refractory patient population, as we have seen in the analysis from preamble registry. We have to focus on difficult to treat patients also in terms of high-risk cytogenetics and we have seen from the sub-analysis of DREAMM-7 to which me and my institution have contributed that belamaf is a potential game changer also in this subset of the patient. I think that all these novelties take us to hope more and more that the cure for our patient is not so far and this is the best wish that I give to our patients, to their caregivers and to all myeloma researchers. Thank you for your attention.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.